Search Results - "Wongchenko, Matthew J"

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2 by Foster, Scott A., Whalen, Daniel M., Özen, Ayşegül, Wongchenko, Matthew J., Yin, JianPing, Yen, Ivana, Schaefer, Gabriele, Mayfield, John D., Chmielecki, Juliann, Stephens, Philip J., Albacker, Lee A., Yan, Yibing, Song, Kyung, Hatzivassiliou, Georgia, Eigenbrot, Charles, Yu, Christine, Shaw, Andrey S., Manning, Gerard, Skelton, Nicholas J., Hymowitz, Sarah G., Malek, Shiva

“…Activating mutations in protein kinases drive many cancers. While how recurring point mutations affect kinase activity has been described, the effect of…”
Get full text

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer by Taraborrelli, Lucia, Şenbabaoğlu, Yasin, Wang, Lifen, Lim, Junghyun, Blake, Kerrigan, Kljavin, Noelyn, Gierke, Sarah, Scherl, Alexis, Ziai, James, McNamara, Erin, Owyong, Mark, Rao, Shilpa, Calviello, Aslihan Karabacak, Oreper, Daniel, Jhunjhunwala, Suchit, Argiles, Guillem, Bendell, Johanna, Kim, Tae Won, Ciardiello, Fortunato, Wongchenko, Matthew J., de Sauvage, Frederic J., de Sousa e Melo, Felipe, Yan, Yibing, West, Nathaniel R., Murthy, Aditya

“…Microsatellite-stable colorectal cancer (MSS-CRC) is highly refractory to immunotherapy. Understanding tumor-intrinsic determinants of immunotherapy resistance…”
Get full text

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS by Kim, Sung-Bae, Dent, Rebecca, Wongchenko, Matthew J, Singel, Stina M, Baselga, José

“…Compared with tissue sequencing, ctDNA sequencing could offer improved time efficiency (avoiding the need to retrieve tissue blocks or perform biopsy), reduced…”
Get full text

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models by Gozgit, Joseph M., Squillace, Rachel M., Wongchenko, Matthew J., Miller, David, Wardwell, Scott, Mohemmad, Qurish, Narasimhan, Narayana I., Wang, Frank, Clackson, Tim, Rivera, Victor M.

“…Purpose Activating mutations in FGFR2 have been identified as potential therapeutic targets in endometrial cancer, typically occurring alongside genetic…”
Get full text

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial by Sweeney, Christopher, Bracarda, Sergio, Sternberg, Cora N, Chi, Kim N, Olmos, David, Sandhu, Shahneen, Massard, Christophe, Matsubara, Nobuaki, Alekseev, Boris, Parnis, Francis, Atduev, Vagif, Buchschacher, Gary L, Gafanov, Rustem, Corrales, Luis, Borre, Michael, Stroyakovskiy, Daniil, Alves, Gustavo Vasconcelos, Bournakis, Evangelos, Puente, Javier, Harle-Yge, Marie-Laurence, Gallo, Jorge, Chen, Geng, Hanover, Justin, Wongchenko, Matthew J, Garcia, Josep, de Bono, Johann S

“…The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss…”
Get full text

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients by Sullivan, Ryan J., Hamid, Omid, Gonzalez, Rene, Infante, Jeffrey R., Patel, Manish R., Hodi, F. Stephen, Lewis, Karl D., Tawbi, Hussein A., Hernandez, Genevive, Wongchenko, Matthew J., Chang, YiMeng, Roberts, Louise, Ballinger, Marcus, Yan, Yibing, Cha, Edward, Hwu, Patrick

“…Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or…”
Get full text

Robust network inference using response logic by Gross, Torsten, Wongchenko, Matthew J, Yan, Yibing, Blüthgen, Nils

“…Abstract Motivation A major challenge in molecular and cellular biology is to map out the regulatory networks of cells. As regulatory interactions can…”
Get full text

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial by Turner, Nicholas, Dent, Rebecca A., O’Shaughnessy, Joyce, Kim, Sung-Bae, Isakoff, Steven J., Barrios, Carlos, Saji, Shigehira, Bondarenko, Igor, Nowecki, Zbigniew, Lian, Qinshu, Reilly, Sarah-Jayne, Hinton, Heather, Wongchenko, Matthew J., Kovic, Bruno, Mani, Aruna, Oliveira, Mafalda

“…Purpose PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib–paclitaxel…”
Get full text

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer by Shi, Zhen, Wulfkuhle, Julia, Nowicka, Malgorzata, Gallagher, Rosa I, Saura, Cristina, Nuciforo, Paolo G, Calvo, Isabel, Andersen, Jay, Passos-Coelho, José Luis, Gil-Gil, Miguel J, Bermejo, Begoña, Pratt, Debra A, Ciruelos, Eva M, Villagrasa, Patricia, Wongchenko, Matthew J, Petricoin, Emanuel F, Oliveira, Mafalda, Isakoff, Steven J

“…Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated and how tumors are…”
Get full text

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial by Dent, Rebecca A, Kim, Sung-Bae, Oliveira, Mafalda, Barrios, Carlos, O'Shaughnessy, Joyce, Isakoff, Steven J, Saji, Shigehira, Freitas-Junior, Ruffo, Philco, Manuel, Bondarenko, Igor, Lian, Qinshu, Bradley, Denise, Hinton, Heather, Wongchenko, Matthew J, Reilly, Sarah-Jayne, Turner, Nicholas

“…In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free…”
Get full text

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma by Daemen, Anneleen, Cooper, Jonathan E, Myrta, Szymon, Wongchenko, Matthew J, Lin, Eva, Long, Jason E, Foreman, Oded, Modrusan, Zora, Tremayne, Jarrod R, de la Cruz, Cecile C, Merchant, Mark, Martin, Scott E, Yan, Yibing, Junttila, Melissa R

“…Lung adenocarcinomas comprise the largest fraction of non-small cell lung cancer, which is the leading cause of cancer-related deaths. Seventy-five percent of…”
Get full text

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation by Long, Jason E., Wongchenko, Matthew J., Nickles, Dorothee, Chung, Wei-Jen, Wang, Bu-er, Riegler, Johannes, Li, Ji, Li, Qingling, Sandoval, Wendy, Eastham-Anderson, Jeff, Modrusan, Zora, Junttila, Teemu, Carano, Richard A. D., Foreman, Oded, Yan, Yibing, Junttila, Melissa R.

“…Emerging research suggests that multiple tumor compartments can influence treatment responsiveness and relapse, yet the search for therapeutic resistance…”
Get full text

Next-Generation Estrogen Receptor-Targeted Therapeutics by Fernando, Tharu M, Moore, Heather M, Wongchenko, Matthew J, Metcalfe, Ciara

“…Estrogen receptor (ER) α is expressed in the vast majority of breast cancers and is one of the most successfully prosecuted drug targets in oncology, with…”
Get full text

Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib by Wongchenko, Matthew J, McArthur, Grant A, Dréno, Brigitte, Larkin, James, Ascierto, Paolo A, Sosman, Jeffrey, Andries, Luc, Kockx, Mark, Hurst, Stephen D, Caro, Ivor, Rooney, Isabelle, Hegde, Priti S, Molinero, Luciana, Yue, Huibin, Chang, Ilsung, Amler, Lukas, Yan, Yibing, Ribas, Antoni

“…The association of tumor gene expression profiles with progression-free survival (PFS) outcomes in patients with -mutated melanoma treated with vemurafenib or…”
Get full text

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma by Yan, Yibing, Wongchenko, Matthew J, Robert, Caroline, Larkin, James, Ascierto, Paolo A, Dréno, Brigitte, Maio, Michele, Garbe, Claus, Chapman, Paul B, Sosman, Jeffrey A, Shi, Zhen, Koeppen, Hartmut, Hsu, Jessie J, Chang, Ilsung, Caro, Ivor, Rooney, Isabelle, McArthur, Grant A, Ribas, Antoni

“…Previous investigations identified transcriptional signatures associated with innate resistance to anti-programmed cell death protein 1 therapy in melanoma…”
Get full text

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib by Wongchenko, Matthew J., Ribas, Antoni, Dréno, Brigitte, Ascierto, Paolo A., McArthur, Grant A., Gallo, Jorge D., Rooney, Isabelle A., Hsu, Jessie, Koeppen, Hartmut, Yan, Yibing, Larkin, James

“…Summary The prognostic significance of programmed death ligand‐1 (PD‐L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not…”
Get full text

Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition by Wagle, Marie-Claire, Wongchenko, Matthew J., Ramakrishnan, Vanitha, Hampton, Garret, Yan, Yibing

“…Abstract Purpose: Chronic myeloid leukemia (CML) can be effectively treated with BCR-ABL inhibitors such as imatinib, dasatinib, and nilotinib; however,…”
Get full text

Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC by Sweeney, Christopher, Graf, Ryon, Fabrizio, David, Yuen, Kobe, Wongchenko, Matthew J., Gupta, Pratyush, Hegde, Priti, Oxnard, Geoffrey R., Powles, Thomas

“…LBA249 Background: IMbassador250 was a prospective phase III international trial which showed no overall survival (OS) benefit for adding atezolizumab to…”
Get full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial by Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, Kim, Sung-Bae, Lee, Keun Seok, Im, Seock-Ah, Espié, Marc, Wang, Hwei-Chung, Blau, Sibel, Dent, Rebecca, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Oliveira, Mafalda, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, Seigel, Leonard

“…The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast…”
Get full text

Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC) by Sweeney, Christopher, Petry, Russell, Xu, Chang, Graf, Ryon, Fabrizio, David, He, Jie, Gjoerup, Ole, Pasquina, Lincoln, Assaf, Zoe June, Yuen, Kobe, Wongchenko, Matthew J., Gupta, Pratyush, Mariathasan, Sanjeev, Powles, Thomas

“…196 Background: IMbassador250 (IM250) was a prospective phase III trial which showed no overall survival (OS) benefit for adding atezolizumab to enzalutamide…”
Get full text